دورية أكاديمية
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
| العنوان: | Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). |
|---|---|
| المؤلفون: | Solis-Hernandez, Mª Pilar, Fernandez Del Valle, Ana, Carmona-Bayonas, Alberto, Garcia-Carbonero, Rocio, Custodio, Ana, Benavent, Marta, Alonso Gordoa, Teresa, Nuñez-Valdovino, Bárbara, Sanchez Canovas, Manuel, Matos, Ignacio, Alonso, Vicente, Lopez, Carlos, Viudez, Antonio, Izquierdo, Marta, Calvo-Temprano, David, Grande, Enrique, Capdevila, Jaume, Jimenez-Fonseca, Paula |
| سنة النشر: | 2019 |
| المجموعة: | Sistema Sanitario Público de Andalucía (SSPA): Repositorio |
| مصطلحات موضوعية: | Adult, Aged, 80 and over, Antineoplastic Agents, Confidence Intervals, Female, Humans, Male, Middle Aged, Neuroendocrine Tumors, Pancreatic Neoplasms, Progression-Free Survival, Proportional Hazards Models, Prospective Studies, Response Evaluation Criteria in Solid Tumors, Sunitinib, Tomography, X-Ray Computed, Tumor Burden, Young Adult |
| الوصف: | The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. A multicentre, prospective study was conducted in 10 Spanish centres. Computed tomographies, at least every 6 months, were centrally evaluated until tumour progression. One hundred and seven patients were included. Median progression-free survival (PFS) by RECIST and Choi were 11.42 (95% confidence interval [CI], 9.7-15.9) and 15.8 months (95% CI, 13.9-25.7). PFS by Choi (Kendall's τ = 0.72) exhibited greater correlation with overall survival (OS) than PFS by RECIST (Kendall's τ = 0.43). RECIST incorrectly estimated prognosis in 49.6%. Partial response rate increased from 12.8% to 47.4% with Choi criteria. Twenty-four percent of patients with progressive disease according to Choi had stable disease as per RECIST, overestimating treatment effect. Choi criteria predicted PFS/OS. Changes in attenuation occurred early and accounted for 21% of the variations in tumour volume. Attenuation and tumour growth rate (TGR) were associated with improved survival. Choi criteria were able to capture sunitinib's activity in a clinically significant manner better than RECIST; their implementation in standard clinical practice shall be strongly considered in PanNET patients treated with this drug. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1532-1827 |
| العلاقة: | http://hdl.handle.net/10668/14466Test; PMC6889276; https://www.nature.com/articles/s41416-019-0558-7.pdfTest; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889276/pdfTest |
| DOI: | 10.1038/s41416-019-0558-7 |
| الإتاحة: | https://doi.org/10.1038/s41416-019-0558-7Test http://hdl.handle.net/10668/14466Test https://www.nature.com/articles/s41416-019-0558-7.pdfTest https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889276/pdfTest |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; open access |
| رقم الانضمام: | edsbas.FB3DE30A |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 15321827 |
|---|---|
| DOI: | 10.1038/s41416-019-0558-7 |